A dialogue on analogues Newer vitamin-D drugs for use in bone disease, psoriasis, and cancer
- 30 November 1993
- journal article
- research article
- Published by Elsevier in Trends in Endocrinology & Metabolism
- Vol. 4 (9), 297-303
- https://doi.org/10.1016/1043-2760(93)90049-k
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Two nuclear signalling pathways for vitamin DNature, 1993
- EB1089: A new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitroBiochemical Pharmacology, 1992
- 9-cis retinoic acid is a high affinity ligand for the retinoid X receptorCell, 1992
- Vitamin D analogs with low affinity for the vitamin D binding protein: Enhanced in vitro and decreased in vivo activityJournal of Bone and Mineral Research, 1991
- Topical calcipotriol treatment in advanced breast cancerThe Lancet, 1991
- Long-term treatment with calcitriol in postmenopausal osteoporosisMetabolism, 1990
- The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion.JCI Insight, 1989
- Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D. A role for increased sensitivity to calcium.JCI Insight, 1989
- Vitamin D Receptors: Nature and FunctionAnnual Review of Nutrition, 1986
- 1,25 Dihydroxyvitamin D increases hepatocyte cytosolic calcium levels. A potential regulator of vitamin D-25-hydroxylase.JCI Insight, 1986